Evaluation of the Safety and Efficacy of Selective Retina Therapy Laser Treatment in Patients with Central Serous Chorioretinopathy
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: To assess the safety and efficacy of selective retina therapy (SRT) using a Q-switched neodymium-doped yttriumlithium fluoride laser with feedback systems in patients with idiopathic central serous chorioretinopathy (CSC). Methods: This randomized clinical trial enrolled patients having at least 3-month symptom of CSC. From month 3 visit, allsubjects in both groups were eligible for SRT retreatment if they showed persistent or recurrent subretinal fluid (SRF). The primaryoutcome was complete resolution of SRF by optical coherence tomography at 3 months after treatment. The secondaryoutcomes were changes in SRF, central macular thickness (CMT) and best-corrected visual acuity at the 1-, 3-, and 6-monthexaminations. Results: Sixty-eight CSC patients were included (SRT, 31; control, 37). After 1 and 3 months, complete resolution of SRF wasachieved in 25.8% and 54.8% of SRT group and 17.6% and 35.1% of controls. The differences were not statistically significant(p = 0.424 and p = 0.142, respectively). However, mixed model for repeated measures analyses showed that the reduction ofSRF and CMT were observed earlier in SRT group than in the sham group (least squares mean difference, -59.7 μm; 95% confidenceinterval, -98.2 to -21.2; p = 0.0029; least squares mean difference -67.0 μm; 95% confidence interval, -104.8 to -29.2;p = 0.0007, respectively). Significant reduction of SRF (≥50% reduction from baseline) was more frequently observed in SRTgroup (80.6%) than the sham group (44.1%) at month 1 (p = 0.007). Early reduction of SRF and CMT was more abundant inSRT group with symptom duration less than 6 months. Treatment related serious adverse events were not observed. Conclusions: SRT using a Q-switched neodymium-doped yttrium lithium fluoride laser with feedback system was safe in thistrial and effective for early resolution of SRF in the CSC patients. Early intervention with SRT can be a safe alternative for patientswith acute symptomatic CSC.
Abstract
Purpose: To assess the safety and efficacy of selective retina therapy (SRT) using a Q-switched neodymium-doped yttriumlithium fluoride laser with feedback systems in patients with idiopathic central serous chorioretinopathy (CSC). Methods: This randomized clinical trial enrolled patients having at least 3-month symptom of CSC. From month 3 visit, allsubjects in both groups were eligible for SRT retreatment if they showed persistent or recurrent subretinal fluid (SRF). The primaryoutcome was complete resolution of SRF by optical coherence tomography at 3 months after treatment. The secondaryoutcomes were changes in SRF, central macular thickness (CMT) and best-corrected visual acuity at the 1-, 3-, and 6-monthexaminations. Results: Sixty-eight CSC patients were included (SRT, 31; control, 37). After 1 and 3 months, complete resolution of SRF wasachieved in 25.8% and 54.8% of SRT group and 17.6% and 35.1% of controls. The differences were not statistically significant(p = 0.424 and p = 0.142, respectively). However, mixed model for repeated measures analyses showed that the reduction ofSRF and CMT were observed earlier in SRT group than in the sham group (least squares mean difference, -59.7 μm; 95% confidenceinterval, -98.2 to -21.2; p = 0.0029; least squares mean difference -67.0 μm; 95% confidence interval, -104.8 to -29.2;p = 0.0007, respectively). Significant reduction of SRF (≥50% reduction from baseline) was more frequently observed in SRTgroup (80.6%) than the sham group (44.1%) at month 1 (p = 0.007). Early reduction of SRF and CMT was more abundant inSRT group with symptom duration less than 6 months. Treatment related serious adverse events were not observed. Conclusions: SRT using a Q-switched neodymium-doped yttrium lithium fluoride laser with feedback system was safe in thistrial and effective for early resolution of SRF in the CSC patients. Early intervention with SRT can be a safe alternative for patientswith acute symptomatic CSC.
참고문헌 (24)
- Rim TH, "Association of corticosteroid use with incidence of central serous chorioretinopathy in South Korea", JAMA Ophthalmol, 136, pp.1164~1169 (2018)
- Daruich A, "Central serous chorioretinopathy: recent findings and new physiopathology hypothesis", Prog Retin Eye Res, 48, pp.82~118 (2015)
- Fok AC, "Risk factors for recurrence of serous macular detachment in untreated patients with central serous chorioretinopathy", Ophthalmic Res, 46, pp.160~163 (2011)
- Matet A, "Risk factors for recurrences of central serous chorioretinopathy", Retina, 38, pp.1403~1414 (2018)
- Ooto S, "High-resolution imaging of resolved central serous chorioretinopathy using adaptive optics scanning laser ophthalmoscopy", Ophthalmology, 117, pp.1800~1809 (2010)
- Robertson DM, "Argon laser photocoagulation treatment in central serous chorioretinopathy", Ophthalmology, 93, pp.972~974 (1986)
- Roider J, "Retinal sparing by selective retinal pigment epithelial photocoagulation", Arch Ophthalmol, 117, pp.1028~1034 (1999)
- Elsner H, "Selective retina therapy in patients with central serous chorioretinopathy", Graefes Arch Clin Exp Ophthalmol, 244, pp.1638~1645 (2006)
- Kang S, "Selective retina therapy in patients with chronic central serous chorioretinopathy: a pilot study", Medicine (Baltimore), 95, pp.e2524~ (2016)
- Park YG, "Selective retina therapy with automatic real-time feedback-controlled dosimetry for chronic central serous chorioretinopathy in Korean patients", Graefes Arch Clin Exp Ophthalmol, 255, pp.1375~1383 (2017)
- Schmidt-Erfurth U, "Application of automated quantification of fluid volumes to anti-VEGF therapy of neovascular age-related macular degeneration", Ophthalmology, 127, pp.1211~1219 (2020)
- Sramek C, "Non-damaging retinal phototherapy: dynamic range of heat shock protein expression", Invest Ophthalmol Vis Sci, 52, pp.1780~1787 (2011)
- Hata M, "Early changes in foveal thickness in eyes with central serous chorioretinopathy", Retina, 33, pp.296~301 (2013)
- Ahn SE, "Three-dimensional configuration of subretinal fluid in central serous chorioretinopathy", Invest Ophthalmol Vis Sci, 54, pp.5944~5952 (2013)
- Chakravarthy U, "Association between visual acuity, lesion activity markers and retreatment decisions in neovascular age-related macular degeneration", Eye (Lond), 34, pp.2249~2256 (2020)
- Kim YJ, "Selective retina therapy with real-time feedback-controlled dosimetry for treating acute idiopathic central serous chorioretinopathy in Korean patients", J Ophthalmol, 2018, pp.6027871~ (2018)
- Abd Elhamid AH, "Subthreshold micropulse yellow laser treatment for nonresolving central serous chorioretinopathy", Clin Ophthalmol, 9, pp.2277~2283 (2015)
- Roisman L, "Micropulse diode laser treatment for chronic central serous chorioretinopathy: a randomized pilot trial", Ophthalmic Surg Lasers Imaging Retina, 44, pp.465~470 (2013)
- Arora S, "Subthreshold diode micropulse laser versus observation in acute central serous chorioretinopathy", Clin Exp Optom, 102, pp.79~85 (2019)
- van Dijk E, "Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy: the PLACE trial", Ophthalmology, 125, pp.1547~1555 (2018)
- Lim JI, "Collaborative retrospective macula society study of photodynamic therapy for chronic central serous chorioretinopathy", Ophthalmology, 121, pp.1073~1078 (2014)
- Wang SK, "Mineralocorticoid receptor antagonists in central serous chorioretinopathy: a meta-analysis of randomized controlled trials", Ophthalmol Retina, 3, pp.154~160 (2019)
- Lotery A, "Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial", Lancet, 395, pp.294~303 (2020)
- Ji S, "Clinical efficacy of anti-VEGF medications for central serous chorioretinopathy: a meta-analysis", Int J Clin Pharm, 39, pp.514~521 (2017)